For immediate release
Chicago, IL – October 14, 2024 – Stocks in this week’s article are Atour Lifestyle Holdings Ltd. ATAT, Vertiv Holdings Co. VRT, Corcept Therapeutics Inc. CORT, Qifu Technology Inc. QFIN, and ADMA Biologics Inc. ADMA .
5 stocks with strong stock prices recently despite October’s volatility
Wall Street remained volatile in October. This year, the U.S. stock market has been experiencing increased volatility since the beginning of this month. We expect volatility to continue in October due to better-than-expected September jobs numbers, expectations that the Fed will cut rates gradually rather than in a more aggressive manner, and a sharp rise in benchmark 10-year Treasury yields. be done. Geopolitical conflicts in the Middle East and the November 5th US presidential election.
As a result, several stocks showed strength in their share prices. We primarily targeted stocks that have been trending upward recently. Stocks like this are likely to carry the momentum going forward.
The five stocks in question are Atour Lifestyle Holdings Ltd., Vertiv Holdings Co., Corcept Therapeutics Inc., Qifu Technology Inc., and ADMA Biologics Inc.
If stock prices are consistently trending upward, there must be a clear reason. If it wasn’t, it probably would have crashed. Therefore, it seems reasonable to focus on stocks that have the potential to outperform their self-set benchmarks.
But recent price strength alone cannot create magic. Therefore, other relevant parameters are required to create a successful investment strategy.
Here’s how to create a screen to shortlist current and potential winners.
Let’s discuss five of these 16 stocks.
Atour Lifestyle Holdings Ltd. develops lifestyle brands centered on hotels in the People’s Republic of China. ATAT provides hotel management services to its franchisees, including day-to-day hotel management services. We sell hotel supplies and other products.
ATAT also provides retail management services. Investment management services. Financial information services management. Real estate management services. In addition to software and technology services, the company also operates a travel agency.
Atul Lifestyle Holdings stock has increased 39% in the past four weeks. The company expects profit growth to be 32.6% for the current fiscal year. The Zacks Consensus Estimate for this year has improved 10.9% over the past 60 days.
Vertiv Holdings Co. designs, manufactures and services critical digital infrastructure technologies and lifecycle services for data centers, communications networks, commercial and industrial environments in the Americas, Asia Pacific, Europe, the Middle East and Africa. . VRT provides hardware, software, analytics, and ongoing services.
story continues
Vertiv Holdings stock has increased 31.2% over the past four weeks. The expected profit growth rate for this fiscal year is 45.8%. The Zacks Consensus Estimate for current-year earnings has improved 6.2% over the past 90 days.
Corcept Therapeutics Inc. is engaged in the discovery and development of medicines for the treatment of severe endocrine, oncological, metabolic, and neurological diseases in the United States. Korlym is available for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome and in patients with type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery. We offer tablets.
CORT is also developing Lilacolilant for the treatment of Cushing’s syndrome, in Phase 3 clinical trials, as a treatment for adrenal cancer and cortisol excess (in Phase 1b clinical trials), and in the treatment of prostate cancer. (in Phase 2 clinical trials), and research and development. Combination of paclitaxel and lilacolilant. It is in Phase III clinical trials to treat platinum-resistant ovarian tumors.
Corcept Therapeutics stock has increased 29.2% over the past four weeks. The expected profit growth rate for this fiscal year is 19.2%. The Zacks Consensus Estimate for current-year earnings has improved 1.8% over the past 30 days.
Qifu Technology Inc. operates as a credit technology platform in the People’s Republic of China under the 360 Jietiao brand. QFIN provides credit-driven services that match borrowers with financial institutions to perform customer acquisition, initial and credit screening, advanced risk assessment, credit scoring, funds matching, and other post-facilitation and platform services. Provide. QFIN also offers e-commerce loans, enterprise loans, and invoicing loans for small business owners. QFIN serves financial institutions, consumers, small businesses and micro businesses.
Qifu Technology’s stock price has increased by 25% over the past four weeks. The company expects profit growth to be 38% this fiscal year. The Zacks Consensus Estimate for this year has improved 2.8% over the past 30 days.
ADMA Biologics Inc. is an immunoglobulin specialty company. ADMA plans to develop, manufacture and market plasma-based biologics for the treatment and prevention of certain infectious diseases.
Targeted patient populations for ADMA include immunocompromised patients with underlying immunodeficiency diseases and patients who are immunosuppressed for medical reasons. ADMA’s lead product candidate, RI-002, is in Phase III clinical trials for the treatment of primary immunodeficiency diseases.
ADMA Biologics stock has increased 20.2% over the past four weeks. Next year’s profit growth rate is expected to be 29.6%. The Zacks Consensus Estimate for next year’s earnings has improved 8.5% over the past 60 days.
Get the rest of the stocks on this list and start using this screen in your own trading by signing up for a 2-week free trial of Research Wizard today. Additionally, you can create and test your own strategies before investing.
Research Wizard is a great place to start. It’s easy to use. Everything is written in plain language. And it’s very intuitive. Start your Research Wizard trial today. Then, the next time you read an economic report, open the Research Wizard, enter your search results, and see what valuable information you can uncover.
Click here to sign up for a free trial of Research Wizard today.
For the rest of this Week in Screens article, visit Zacks.com (https://www.zacks.com/stock/news/2349113/5-stocks-with-recent-price-strength-amid-october-volatility) Please take a look.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or sell the securities or hold long and/or short options positions in the securities mentioned herein. there is. The affiliated investment advisory firm may own or sell securities or hold long and/or short options positions in the securities mentioned herein.
About this week’s screen
Zacks.com creates the first and best screening system on the web and was honored by Money Magazine as the “#1 Site to Screen Stocks.” But powerful screening tools are just the beginning. That’s why Zack created the “Screen of the Week” to highlight profitable stock-picking strategies that investors can actively utilize.
Strong stocks that should be in the news
Many of them are barely publicized and are off Wall Street’s radar. They are little known to the general public. But today’s 220 Zacks Rank #1 Strong Buy was created by a stock-picking system that more than doubled the market from 1988 to 2016. Its average return is an impressive +25% per year. See these high-potential stocks for free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated companies (including broker-dealers and investment advisers) and may enter into transactions related to the aforementioned securities on behalf of the affiliated companies’ clients.
Contact: Jim Giaquinto
Company Name: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Access: https://www.zacks.com/
Zacks.com provides investment resources and informs you about these resources. You may choose to use these resources for your own investment decisions. Zacks provides information about this resource subject to the disclaimer in the Zacks Terms of Use. www.zacks.com/Disclaimer.
Past performance does not guarantee future results. Any investment involves the possibility of loss. This material is provided for informational purposes only and does not constitute investment, legal, accounting, or tax advice or a recommendation to buy, sell, or hold any security. No recommendation or advice is given as to whether an investment is suitable for any particular investor. It should not be assumed that an investment in the securities, companies, sectors or markets identified and described has been or will be profitable. All information is current as of the date of this document and is subject to change without notice. The views and opinions expressed may not reflect those of the Company as a whole. Zacks Investment Research does not engage in investment banking, market making, or securities asset management activities. These returns are from a hypothetical portfolio of Zacks Rank = 1 stocks that is rebalanced monthly with zero trading costs. These are not actual stock portfolio returns. The S&P 500 is an unmanaged index. For information on the performance numbers displayed in this press release, please visit https://www.zacks.com/performance.
Want the latest recommendations from Zacks Investment Research? Today you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
Qifu Technology, Inc. (QFIN): Free Stock Analysis Report
Vertiv Holdings Co. (VRT): Free Stock Analysis Report
Atul Lifestyle Holdings Limited Sponsored ADR (ATAT): Free Stock Analysis Report
Click here to read this article on Zacks.com.
Zacks Investment Research
